European Pharmaceutical Review

JUNE 24, 2022

This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused Maarten has significant competition law experience in a variety of sectors. About the author. References.

Pharmaceutical 105

Pharmaceutical Medicine Marketing Competition 105

PM360

SEPTEMBER 28, 2022

Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar being approved in Europe in 2006. he is responsible for leading the commercialization efforts of specialty products which includes a broad portfolio of biosimilars. The level of competition is much greater today then we previously anticipated.

Competition 98

Competition Marketing Manufacturing Biopharma 98

The Brooks Group

FEBRUARY 23, 2009

The competition at this year's annual awards for sales and customer service once again featured some of America's top sales professionals and forward-thinking organizations. These nominations follow TBG's 2006 win as Consulting Sales Organization of the Year. The Brooks Group remains among the sales professional's elite companies.

Recruitment 40

Recruitment Sales Sales process Sales Management 40

The Brooks Group

FEBRUARY 23, 2009

The competition at this year's annual awards for sales and customer service once again featured some of America's top sales professionals and forward-thinking organizations. These nominations follow TBG's 2006 win as Consulting Sales Organization of the Year. The Brooks Group remains among the sales professional's elite companies.

Recruitment 40

Recruitment Sales Sales process Sales Management 40

Pharmaceutical Technology

MARCH 24, 2023

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. Further, there remains scepticism on the efficacy and safety of biosimilars.

Competition 59

Competition Marketing FDA Physicians 59

Healthcare Success

JULY 5, 2022

How to create marketing and lead generation systems that get results. Editor’s Note: I wrote the first version of this blog post back in 2006 when we launched Healthcare Success. Thus, marketing and lead acquisition costs can quickly spiral to the point of unprofitability. Lead Generation Best Practices.

Doctors 57

Doctors Physicians Marketing Healthcare 57

European Pharmaceutical Review

DECEMBER 19, 2022

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Medicine 52

Medicine Biopharma Safety Food 52